Biohaven gets rights to AZ's myeloperoxidase inhibitor

AstraZeneca plc (NYSE:AZN; LSE:AZN) granted the Biohaven Therapeutics Ltd. subsidiary of Biohaven

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE